IN8bio Inc Dossier
Qualitative Analysis
Business overview
IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative gamma-delta T cell product candidates for the treatment of cancers and autoimmune diseases. Utilizing its proprietary DeltEx platform, the company develops allogeneic, autologous, and genetically modified cellular therapies designed to effectively identify and eradicate tumor cells while sparing healthy tissue. Its pipeline includes INB-100, an allogeneic product candidate in Phase 1 clinical trials for hematologic malignancies undergoing hematopoietic stem cell transplantation, and INB-200, a genetically modified autologous gamma-delta T cell therapy for newly diagnosed glioblastoma (GBM). Additionally, the company is advancing its next-generation T cell engager (TCE) platform, including INB-619, which targets CD19 for oncology and autoimmune indications such as systemic lupus erythematosus (SLE).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
In September 2024, IN8bio implemented a corporate restructuring that included a 49% headcount reduction and the suspension of enrollment in the Phase 2 trial of INB-400 in glioblastoma. This allowed the company to conserve cash and focus its primary clinical resources on advancing its top-priority allogeneic candidate, INB-100, for AML.
Expected impact: Significantly reduced R&D expenses (down 36% YoY in 2025) and extended the company's cash runway.
Development of the novel INB-600 platform, featuring gamma-delta T-cell engagers (TCEs) that target CD19. The lead candidate, INB-619, is designed to activate gamma-delta T cells without engaging CD3, potentially offering a safer, off-the-shelf alternative to traditional CAR-T therapies for oncology and autoimmune diseases.
Expected impact: Diversifies the company's therapeutic modalities beyond oncology into high-growth autoimmune indications.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Coastlands Capital led a critical private placement of up to $40.2 million in December 2025. The structured deal provided an immediate $20.1 million in cash to extend the runway into 2027, with an additional milestone-based $20.1 million tied to the development of the INB-619 program.
Terms: Initial tranche of $20.1 million completed in December 2025 at $1.38 per share, with pre-funded warrants.